Invivyd (IVVD) Asset Utilization Ratio (2024 - 2025)
Invivyd posted quarterly Asset Utilization Ratio of 0.26 for Q4 2025, up 47.44% year-on-year from 0.17 in Q4 2024, and down 41.41% on a QoQ basis from 0.44 in Q3 2025.
Invivyd (IVVD) has 2 years of Asset Utilization Ratio data on file, last reported at 0.26 in Q4 2025.
- For the quarter ending Q4 2025, Asset Utilization Ratio rose 47.44% year-over-year to 0.26; the trailing twelve-month figure through Dec 2025 stood at 0.26 (up 47.44% YoY), and the FY2025 full-year result was 0.26, up 85.77% from the prior year.
- Asset Utilization Ratio for Q4 2025 stood at 0.26, down from 0.44 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.48 in Q2 2025 and bottomed at 0.01 in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.85 |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - | 0.26 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.26 |
| Sep 30, 2025 | 0.44 |
| Jun 30, 2025 | 0.48 |
| Mar 31, 2025 | 0.31 |
| Dec 31, 2024 | 0.17 |
| Sep 30, 2024 | 0.07 |
| Jun 30, 2024 | 0.01 |